AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23194490 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with testosterone
Number of subjects: 41
Study 23194490 — intervention group
Group type: COMPARATOR
Intervention: Exercise with placebo
Number of subjects: 41
Study 20020312 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (weak intervention)
Number of subjects: 49
Study 20020312 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (strong intervention)
Number of subjects: 49
Study 18824996 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Impact (n = 65)
Number of subjects: 535
Study 18824996 — intervention group
Group type: COMPARATOR
Intervention: Match Control (n = 49)
Number of subjects: 535
Study 18824996 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity Exercise (n = 35)
Number of subjects: 535
Study 18824996 — intervention group
Group type: EXPERIMENTAL
Intervention: Heading (n = 36)
Number of subjects: 535
Study 16000280 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I‐PE2I bolus injection
Number of subjects: 5
Study 16000280 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bolus and constant infusion of 123I‐PE2I
Number of subjects: 5
Study 12833584 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (4 mg, once daily) in combination with ramipril
Number of subjects: 43
Study 12833584 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with ramipril
Number of subjects: 43
Study 10567194 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of sustained‐release nicardipine hydrochloride twice daily
Number of subjects: 414
Study 10567194 — intervention group
Group type: COMPARATOR
Intervention: 2 mg of trichlormethiazide once daily
Number of subjects: 414
Study 8652357 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematics achievement test for Hong Kong Chinese children
Number of subjects: 253
Study 8652357 — intervention group
Group type: COMPARATOR
Intervention: Ratings of children's competence by Canadian respondents
Number of subjects: 253
Study 8652357 — intervention group
Group type: COMPARATOR
Intervention: Harter Self-Perception Profile Scale for Canadian children
Number of subjects: 253
Study 8652357 — intervention group
Group type: COMPARATOR
Intervention: Harter Self-Perception Profile Scale for Hong Kong children
Number of subjects: 253
Study 1818788 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate therapy
Number of subjects: 0
Study 1818788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6346558 — intervention group
Group type: EXPERIMENTAL
Intervention: No parenchymal lymphatic vessel invasion and no lymph node metastasis
Number of subjects: 685
Study 6346558 — intervention group
Group type: EXPERIMENTAL
Intervention: No lymphatic vessel invasion but with lymph node metastasis
Number of subjects: 685
Study 6346558 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic vessel invasion and no lymph node metastasis
Number of subjects: 685
Study 6346558 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic vessel invasion with lymph node metastasis
Number of subjects: 685
Study 6346558 — intervention group
Group type: EXPERIMENTAL
Intervention: No blood vessel invasion and with neither lymph node metastasis nor lymphatic vessel invasion
Number of subjects: 685
Study 6346558 — intervention group
Group type: EXPERIMENTAL
Intervention: Either or one, or both lymph node metastasis or lymphatic vessel invasion present
Number of subjects: 685
Study 6346558 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood vessel invasion without lymph node invasion or lymphatic vessel invasion
Number of subjects: 685
Study 6346558 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood vessel invasion with either one or both lymph node invasion or lymphatic vessel invasion
Number of subjects: 685
Study 3859943 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 20
Study 3859943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30608622 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure plus standard result notification letter
Number of subjects: 105
Study 30608622 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard notification letter alone)
Number of subjects: 105
Study 28827051 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrostatic reduction with normal saline
Number of subjects: 124
Study 28827051 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic reduction with air
Number of subjects: 124
Study 28827051 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrostatic reduction
Number of subjects: 124
Study 27777219 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer
Number of subjects: 72139
Study 27777219 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no screening)
Number of subjects: 72139
Study 24663014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin alone
Number of subjects: 38
Study 24663014 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid alone
Number of subjects: 38
Study 24663014 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid with nevirapine
Number of subjects: 38
Study 24663014 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid with efavirenz
Number of subjects: 38
Study 24663014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin with nevirapine
Number of subjects: 38
Study 24663014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin with efavirenz
Number of subjects: 38
Study 24663014 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pharmacokinetics of rifampin and isoniazid
Number of subjects: 38
Study 23109024 — intervention group
Group type: EXPERIMENTAL
Intervention: New gastric lavage protocol
Number of subjects: 120
Study 23109024 — intervention group
Group type: COMPARATOR
Intervention: Classic gastric lavage method
Number of subjects: 120
Study 20956765 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide at body temperature
Number of subjects: 30
Study 20956765 — intervention group
Group type: COMPARATOR
Intervention: Carbon dioxide at room temperature
Number of subjects: 30
Study 18805108 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 155
Study 18805108 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 155
Study 16082684 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational angiography
Number of subjects: 50
Study 16082684 — intervention group
Group type: COMPARATOR
Intervention: Standard angiography
Number of subjects: 50
Study 12789223 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 210
Study 12789223 — intervention group
Group type: EXPERIMENTAL
Intervention: Other Antihistamines (OAH)
Number of subjects: 210
Study 12789223 — intervention group
Group type: COMPARATOR
Intervention: Nonteratogenic Controls (NTC)
Number of subjects: 210
Study 12789223 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (first trimester)
Number of subjects: 210
Study 12789223 — intervention group
Group type: EXPERIMENTAL
Intervention: Other Antihistamines (OAH) (first trimester)
Number of subjects: 210
Study 12789223 — intervention group
Group type: COMPARATOR
Intervention: Nonteratogenic Controls (NTC) (first trimester)
Number of subjects: 210
Study 11070566 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 0
Study 11070566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11070566 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised feeding regimen
Number of subjects: 0
Study 9082488 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment for primary prevention of coronary heart disease
Number of subjects: 0
Study 1634452 — intervention group
Group type: EXPERIMENTAL
Intervention: Theolan preparation (once a day)
Number of subjects: 10
Study 1634452 — intervention group
Group type: COMPARATOR
Intervention: Theolan preparation (twice a day)
Number of subjects: 10
Study 6499384 — intervention group
Group type: COMPARATOR
Intervention: Magnesium citrate alone
Number of subjects: 2
Study 6499384 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate with bisacodyl (oral or rectal)
Number of subjects: 2
Study 6499384 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate with sodium picosulphate (Picolax)
Number of subjects: 2
Study 30734418 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite-based weight reduction program
Number of subjects: 58
Study 28893752 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory prime
Number of subjects: 0
Study 28893752 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual prime
Number of subjects: 0
Study 28893752 — intervention group
Group type: EXPERIMENTAL
Intervention: Both primes
Number of subjects: 0
Study 28893752 — intervention group
Group type: COMPARATOR
Intervention: Neither prime
Number of subjects: 0
Study 28893752 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall hand hygiene compliance
Number of subjects: 0
Study 28893752 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-acquired infections
Number of subjects: 0
Study 27052741 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed IV fluids
Number of subjects: 52
Study 27052741 — intervention group
Group type: COMPARATOR
Intervention: Room temperature IV fluids (control group)
Number of subjects: 52
Study 25237668 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-guided implant placement aided with templates
Number of subjects: 51
Study 25237668 — intervention group
Group type: COMPARATOR
Intervention: Conventional implant placement without templates
Number of subjects: 51
Study 22424803 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens-based artificial pupil designs
Number of subjects: 0
Study 19492715 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide liner
Number of subjects: 123
Study 19492715 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid composite restorative material
Number of subjects: 123
Study 19492715 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect restoration with buildup material
Number of subjects: 123
Study 19492715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavity depth (shallow, medium, deep)
Number of subjects: 123
Study 17635433 — intervention group
Group type: EXPERIMENTAL
Intervention: Truview blade
Number of subjects: 170
Study 17635433 — intervention group
Group type: COMPARATOR
Intervention: Macintosh blade
Number of subjects: 170
Study 15059707 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 30
Study 15059707 — intervention group
Group type: COMPARATOR
Intervention: Control (no lipid-lowering therapy)
Number of subjects: 30
Study 12452458 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 600 microg orally
Number of subjects: 1686
Study 12452458 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (control)
Number of subjects: 1686
Study 10791608 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional self-management skills course
Number of subjects: 0
Study 10791608 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8683286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine treatment (intravenous and oral) for 3 weeks
Number of subjects: 123
Study 8683286 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 3 weeks
Number of subjects: 123
Study 8683286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine treatment (intravenous and oral) for 3 weeks (compliant patients only)
Number of subjects: 123
Study 1803712 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen Receptor (ER) positive status
Number of subjects: 1095
Study 1803712 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen Receptor (ER) levels greater than 100 fmol/mg protein
Number of subjects: 1095
Study 1803712 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone Receptor (PgR) status
Number of subjects: 1095
Study 1803712 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone Receptor (PgR) levels
Number of subjects: 1095
Study 1803712 — intervention group
Group type: EXPERIMENTAL
Intervention: ER and PgR profiles
Number of subjects: 1095
Study 6360027 — intervention group
Group type: EXPERIMENTAL
Intervention: Methysergide, 8 mg daily
Number of subjects: 0
Study 6360027 — intervention group
Group type: EXPERIMENTAL
Intervention: Methysergide
Number of subjects: 0
Study 31479287 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-task condition (cough testing only)
Number of subjects: 20
Study 31479287 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task condition (counting tones while undergoing cough testing)
Number of subjects: 20
Study 31479287 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task condition
Number of subjects: 20
Study 31479287 — intervention group
Group type: COMPARATOR
Intervention: Single-task condition and Dual-task condition
Number of subjects: 20
Study 29879241 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbial transplant (FMT)
Number of subjects: 0
Study 29879241 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 0
Study 27302362 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG (9 mg/kg per day) plus cognitive training
Number of subjects: 84
Study 27302362 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cognitive training
Number of subjects: 84
Study 26546644 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 54
Study 26546644 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 54
Study 23649850 — intervention group
Group type: COMPARATOR
Intervention: Artificial Tears (AT)
Number of subjects: 42
Study 23649850 — intervention group
Group type: EXPERIMENTAL
Intervention: Punctal Plugs (PP)
Number of subjects: 42
Study 20505508 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 113
Study 20505508 — intervention group
Group type: COMPARATOR
Intervention: Open approach
Number of subjects: 113
Study 19055333 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive interactive neurostimulation (active)
Number of subjects: 37
Study 19055333 — intervention group
Group type: COMPARATOR
Intervention: Sham noninvasive interactive neurostimulation
Number of subjects: 37
Study 19055333 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (active and sham)
Number of subjects: 37
Study 16256278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE) as a screening tool for cognitive impairment
Number of subjects: 10791
Study 16256278 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher MMSE scores in an inpatient detoxification unit
Number of subjects: 10791
Study 16256278 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function impact on follow-up in medical inpatients with unhealthy alcohol use
Number of subjects: 10791
Study 12809958 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg QD
Number of subjects: 297
Study 12809958 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg QD
Number of subjects: 297
Study 12809958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 11015339 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest LPL activity quartile
Number of subjects: 0
Study 11015339 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest LPL activity quartile
Number of subjects: 0
Study 11015339 — intervention group
Group type: EXPERIMENTAL
Intervention: LPL protein mass
Number of subjects: 0
Study 9129860 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin monotherapy
Number of subjects: 0
Study 9129860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1548825 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam 100 mg three times a day for 5 days
Number of subjects: 191
Study 1548825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 3919805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 140
Study 3919805 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 140
Study 30299178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger root (1.425 g/day)
Number of subjects: 32
Study 30299178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 29809257 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Therapy (OMTh)
Number of subjects: 12
Study 29809257 — intervention group
Group type: COMPARATOR
Intervention: Muscle Stretching
Number of subjects: 12
Study 29809257 — intervention group
Group type: COMPARATOR
Intervention: Soft Touch (Sham Intervention)
Number of subjects: 12
Study 27090850 — intervention group
Group type: EXPERIMENTAL
Intervention: Live music therapy
Number of subjects: 84
Study 27090850 — intervention group
Group type: COMPARATOR
Intervention: Recorded mindfulness exercise
Number of subjects: 84
Study 24756128 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (≥180 seconds after delivery)
Number of subjects: 382
Study 24756128 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (ECC) (≤10 seconds after delivery)
Number of subjects: 382
Study 22941041 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided group attending intervention meetings with education on diet, exercise, AI culture, and emotional wellbeing
Number of subjects: 200
Study 22941041 — intervention group
Group type: COMPARATOR
Intervention: Self-managed group receiving printed CVD prevention materials
Number of subjects: 200
Study 21112429 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric strength measurements in neck and trunk region (flexion, extension, lateral flexion); measured over 2 examination days with 2 measurement passes.
Number of subjects: 95
Study 18172036 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic alerts
Number of subjects: 87886
Study 18172036 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand decision support
Number of subjects: 87886
Study 18172036 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87886
Study 15701612 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (4 mL of 2% xylocaine and 1 mL (6 mg) of betamethasone)
Number of subjects: 58
Study 15701612 — intervention group
Group type: COMPARATOR
Intervention: Xylocaine (5 mL of 2% xylocaine alone)
Number of subjects: 58
Study 12928997 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 22
Study 12928997 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 22
Study 10847423 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg alcohol in orange-flavoured drink
Number of subjects: 11
Study 10847423 — intervention group
Group type: COMPARATOR
Intervention: Non-caloric non-alcoholic drink
Number of subjects: 11
Study 10847423 — intervention group
Group type: EXPERIMENTAL
Intervention: Both alcohol and control trials during exercise
Number of subjects: 11
Study 10847423 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol ingestion
Number of subjects: 11
Study 8925753 — intervention group
Group type: EXPERIMENTAL
Intervention: AVE micro-stent implantation with dual antiaggregation treatment (500 mg ticlopidine and 100 mg aspirin daily for 6 weeks)
Number of subjects: 121
Study 7709692 — intervention group
Group type: EXPERIMENTAL
Intervention: human follicular fluid (hFF) treatment
Number of subjects: 26
Study 7709692 — intervention group
Group type: COMPARATOR
Intervention: mini‐CDPG treatment
Number of subjects: 26
Study 3110264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 39
Study 3110264 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 39
Study 31790910 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological empowerment
Number of subjects: 200
Study 31790910 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning component of psychological empowerment
Number of subjects: 200
Study 31790910 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-determination component of psychological empowerment
Number of subjects: 200
Study 29673355 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (25 mg for 4 weeks, then 50 mg for 4 weeks)
Number of subjects: 358
Study 29673355 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine ER (4 mg for 8 weeks)
Number of subjects: 358
Study 26921934 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent non‐pharmacologic intervention (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drug chart review, elimination, oxygenation, pain)
Number of subjects: 50
Study 26921934 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 50
Study 26143942 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lorazepam
Number of subjects: 0
Study 26143942 — intervention group
Group type: COMPARATOR
Intervention: IV diazepam
Number of subjects: 0
Study 23545834 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-antagonist protocol with highly purified uFSH (Bravelle®) 300 IU/day and 0.25 mg/day GnRH-antagonist starting on cycle day 19-21
Number of subjects: 10
Study 23545834 — intervention group
Group type: COMPARATOR
Intervention: Conventional GnRH-antagonist protocol with 150-225 rFSH or HP-HMG/day
Number of subjects: 10
Study 21303564 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching (telephone and face-to-face) over 18 months in addition to usual care
Number of subjects: 1320
Study 21303564 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1320
Study 19849683 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 99
Study 19849683 — intervention group
Group type: COMPARATOR
Intervention: Facemask and oropharyngeal airway
Number of subjects: 99
Study 18046928 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 18046928 — intervention group
Group type: EXPERIMENTAL
Intervention: Future observational studies (PREDICTIVE and IMPROVE)
Number of subjects: 0
Study 14978288 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased cardiovascular fitness (highly fit individuals in Study 1)
Number of subjects: 0
Study 14978288 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (aerobically trained individuals in Study 2)
Number of subjects: 0
Study 14978288 — intervention group
Group type: COMPARATOR
Intervention: Low fitness (low-fit individuals in Study 1)
Number of subjects: 0